Predicting how well biologics work for IBD
Part of Digestive system clinical trials.
This study builds a model to predict which biologic drug will work best for people with active inflammatory bowel disease (IBD). It uses data from patients already treated with biologics to help guide future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of IBD (Crohn's disease or ulcerative colitis).
- Your IBD must be in an active, symptomatic phase.
- You must have received at least one biologic treatment since your diagnosis.
- You must have follow-up test results showing how well the biologic worked for you.
- You cannot have another autoimmune disease that also requires biologic treatment.
- You cannot have serious conditions like cancer or a hole in your intestine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares different biologic medications to see which best prevents Crohn's disease from coming back after intestinal surgery. It may help you if you have had surgery for Crohn's and are starting a biologic drug soon after.
This study looks at what factors help predict how inflammatory bowel disease (IBD) may progress over time. You may be able to join if you are an adult with IBD and fit one of the study groups based on whether you have used TNF-blocking medicines before.
This trial tests whether closely monitoring and adjusting infliximab (a biologic medicine) can help people hospitalized with a moderate-to-severe flare of Crohn's disease, ulcerative colitis, or unclassified inflammatory bowel disease who haven't gotten better with IV steroids. The goal is to improve treatment response and outcomes.
This study looks at blood and/or tissue “molecular” (cell-level) reasons why treatments don’t fully work in adults with Crohn’s disease or ulcerative colitis. If you are starting a biologic or small-molecule medicine and still have moderate to severe symptoms, you may be able to contribute to research that helps improve future care.
This study analyzes your gut bacteria to see if it can predict how well you will respond to Crohn's disease treatments. If you are having a colonoscopy for routine care, you may be eligible.
This trial tests a personalized approach to starting anti-TNF therapy—a common treatment for inflammatory bowel disease (IBD)—in patients who have never taken it before. The goal is to help doctors choose the right anti-TNF medication and dose based on each patient's individual characteristics.
Hear when a new Inflamatory Bowel Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.